Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade, Vojvode Stepe 444a, 11042 Belgrade, Serbia.
Human Technopole, Palazzo Italia, Viale Rita Levi-Montalcini, 1, 20157 Milan, Italy.
Int J Mol Sci. 2024 Sep 21;25(18):10156. doi: 10.3390/ijms251810156.
Gut microbiota (GM), together with its metabolites (such as SCFA, tryptophan, dopamine, GABA, etc.), plays an important role in the functioning of the central nervous system. Various neurological and psychiatric disorders are associated with changes in the composition of GM and their metabolites, which puts them in the foreground as a potential adjuvant therapy. However, the molecular mechanisms behind this relationship are not clear enough. Therefore, before considering beneficial microbes and/or their metabolites as potential therapeutics for brain disorders, the mechanisms underlying microbiota-host interactions must be identified and characterized in detail. In this review, we summarize the current knowledge of GM alterations observed in prevalent neurological and psychiatric disorders, multiple sclerosis, major depressive disorder, Alzheimer's disease, and autism spectrum disorders, together with experimental evidence of their potential to improve patients' quality of life. We further discuss the main obstacles in the study of GM-host interactions and describe the state-of-the-art solution and trends in this field, namely "culturomics" which enables the culture and identification of novel bacteria that inhabit the human gut, and models of the gut and blood-brain barrier as well as the gut-brain axis based on induced pluripotent stem cells (iPSCs) and iPSC derivatives, thus pursuing a personalized medicine agenda for neuropsychiatric disorders.
肠道微生物群(GM)及其代谢物(如 SCFA、色氨酸、多巴胺、GABA 等)在中枢神经系统的功能中起着重要作用。各种神经和精神疾病与 GM 及其代谢物的组成变化有关,这使得它们成为一种潜在的辅助治疗方法。然而,这种关系背后的分子机制还不够清楚。因此,在考虑有益微生物和/或其代谢物作为治疗大脑疾病的潜在疗法之前,必须详细确定和描述微生物群-宿主相互作用的机制。在这篇综述中,我们总结了 GM 改变在常见神经和精神疾病、多发性硬化症、重度抑郁症、阿尔茨海默病和自闭症谱系障碍中的观察结果,以及它们改善患者生活质量的潜力的实验证据。我们进一步讨论了 GM-宿主相互作用研究中的主要障碍,并描述了该领域的最新解决方案和趋势,即“培养组学”,它能够培养和鉴定栖息在人类肠道中的新型细菌,以及基于诱导多能干细胞(iPSC)和 iPSC 衍生物的肠道和血脑屏障模型,以及肠道-大脑轴,从而为神经精神疾病追求个性化医疗方案。